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vention. The main intervention areas were: adverse drug
effects; incorrect dosage; polypharmacy, and drug-drug,
drug-disease and drug-food interactions. Based on this
data, the pharmacist suggested specific changes in drug
treatment including route of administration, changing
dosing, eliminating drug interactions and preventing life-
threatening drug combinations. In addition the clinical
pharmacist provides pharmaceutical information to phy-
sicians and nursing staff.
RESULTS: We reviewed approximately 2300 medical
records and found one or more interventions in 11% of
the cases. The main type of interventions were: 99
(38.9%) unnecessary drugs; 51 (20%) incorrect dose; 47
(18.5%) drug information; 26 (10.2%) adverse drug re-
action; 17 (6.6%) drug-drug interactions, and 14 (5.5%)
therapeutic drug monitoring. It should be emphasized
that 112 drug interactions with varying degrees of sever-
ity were prevented. The physicians, in 96% of all inter-
ventions, accepted the clinical pharmacist’s recommenda-
tions.
CONCLUSION: The results demonstrate that the clinical
pharmacist contributes substantially to the quality of pa-
tient care involving drug-related problems. In addition,
this intervention may reduce length of hospital stay and
lower drug costs.
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OBJECTIVE: To estimate the in-hospital costs of blood
products in German hospitals.
METHODS: Data on personnel-time and material-resource
utilisation associated with blood products were collected
as part of a health-economic study on hospital costs for
Coronary Artery Bypass Graft patients with and without
rethoracotomy in Germany. The real cost to hospitals for
blood products was then calculated based on these data.
The transfusion departments in four hospitals each com-
pleted a questionnaire, giving details of materials and time
required to obtain or to prepare erythrocytes (autologous
and homologous blood) and autologous fresh frozen
plasma. Hospital administration departments provided in-
formation from which personnel costs were calculated.
RESULTS: For homologous erythrocytes, total costs
were 194 DM (99 Euro) per unit of donor red blood
cells. Logistics, testing and materials (e.g. use of transfu-
sion instruments) amounted to a total of 77 DM (39
Euro) in addition to the acquisition costs. On average,
about 50 minutes were spent on ordering, buying, stor-
age, administration, disposal and testing of the banked
blood. The production of one unit from autologous
blood cost 223 DM (114 Euro). Time taken by staff
made up a significant portion of these costs. On average,
130 minutes were necessary for collection of blood, prep-
aration, testing, storage, administration, disposal and re-
testing before the operation. Fresh frozen plasma was ob-
tained during preparation of autologous blood and cost
an extra 31 DM (16 Euro) per unit.
CONCLUSION: This economic analysis of blood prod-
ucts shows that both personnel and material costs for ad-
ditional processing of blood products amount to a signif-
icant part of the total hospital costs. Blood-product
acquisition costs alone may lead to an underestimation of
the economic benefit associated with treatments that po-
tentially reduce the need for blood products.
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OBJECTIVES: To estimate the number of patients and
costs for the treatment of selected diseases in Switzerland,
depending on physical activity level. Calculation of acci-
dents due to sport or other causes.
METHODS: Top-down approach, modeling the number
of cases and deaths due to coronary heart disease (CHD),
hypertension, non-insulin-dependent diabetes (NIDD),
mammary cancer, colon cancer, lower back pain (LBP),
brief recurrent depression, osteoporosis. Distinction by
activity level (active or not). Decision tree model for cal-
culating the number of accidents, disability, and deaths
due to sports and general accidents. Inclusion of direct
costs, indirect costs, and transfer payments. A compari-
son of disease and accident costs was not possible, be-
cause accidents could not be separated by activity level.
RESULTS: The burden of disease is 8.5 billion SFr in di-
rect and 6 billion SFr in indirect costs. The inactive popu-
lation (37%) incurs most of the direct costs (49%, 4.14
billion SFr). Diseases occurring in the active population
(61%) require 2.7 billion SFr a year. Each physically in-
active person costs 2595 SFr per year; active people,
1700 SFr per year. The risks attributable to physical inac-
tivity are: CHD, 24%; hypertension, 15%; NIDD, 24%;
mammary cancer, 12%; colon cancer, 25%; LBP, 12%;
depression, 44%; osteoporosis, 27%. The proportion of
costs for diseases caused by physical inactivity is 16%.
Total number of general accidents is 670,000, plus
299,000 sports-related accidents. 1875 accident-related
deaths occur, with only 161 (9%) of them caused by
sport. The ratio of the yearly direct costs of non-sport/
sport-related accidents is 3.4 / 1.1 billion SFr, and the ra-
